Which Melanoma Patient Carries a BRAF-mutation? A Comparison of Predictive Models

Overview

Journal Oncotarget

Specialty Oncology

Date 2016 May 7

PMID 27150060

Citations 5

Authors

Thomas Eigentler

Zeinab Assi

Jessica C Hassel

Lucie Heinzerling

Hans Starz

Mark Berneburg

Jurgen Bauer

Claus Garbe

Affiliations

Soon will be listed here.

Abstract

Background: In patients with advanced melanoma the detection of BRAF mutations is considered mandatory before the initiation of an expensive treatment with BRAF/MEK inhibitors. Sometimes it is difficult to perform such an analysis if archival tumor tissue is not available and fresh tissue has to be collected.

Results: 514 of 1170 patients (44%) carried a BRAF mutation. All models revealed age and histological subtype of melanoma as the two major predictive variables. Accuracy ranged from 0.65-0.71, being best in the random forest model. Sensitivity ranged 0.76-0.84, again best in the random forest model. Specificity was low in all models ranging 0.51-0.55.

Methods: We collected the clinical data and mutational status of 1170 patients with advanced melanoma and established three different predictive models (binary logistic regression, classification and regression trees, and random forest) to forecast the BRAF status.

Conclusions: Up to date statistical models are not able to predict BRAF mutations in an acceptable accuracy. The analysis of the mutational status by sequencing or immunohistochemistry must still be considered as standard of care.

Citing Articles

Predicting Mutations in Cutaneous Melanoma Patients Using Neural Network Analysis.

Dudin O, Mintser O, Gurianov V, Kobyliak N, Kaminskyi D, Matvieieva A J Skin Cancer. 2024; 2024:3690228.

PMID: 39735251 PMC: 11671645. DOI: 10.1155/jskc/3690228.

Effects of BRAF V600E and NRAS mutational status on the progression-free survival and clinicopathological characteristics of patients with melanoma.

Zablocka T, Kreismane M, Pjanova D, Isajevs S Oncol Lett. 2022; 25(1):27.

PMID: 36478905 PMC: 9713804. DOI: 10.3892/ol.2022.13613.

Addressing the importance of melanoma tumor-infiltrating lymphocytes in disease progression and clinicopathological characteristics.

Zablocka T, Nikolajeva A, Kreismane M, Pjanova D, Isajevs S Mol Clin Oncol. 2021; 15(6):255.

PMID: 34671473 PMC: 8521388. DOI: 10.3892/mco.2021.2417.

BRAF inhibition curtails IFN-gamma-inducible PD-L1 expression and upregulates the immunoregulatory protein galectin-1 in melanoma cells.

Gorniak P, Wasylecka-Juszczynska M, Lugowska I, Rutkowski P, Polak A, Szydlowski M Mol Oncol. 2020; 14(8):1817-1832.

PMID: 32330348 PMC: 7400781. DOI: 10.1002/1878-0261.12695.

Heterogeneity and frequency of BRAF mutations in primary melanoma: Comparison between molecular methods and immunohistochemistry.

Bruno W, Martinuzzi C, Andreotti V, Pastorino L, Spagnolo F, Dalmasso B Oncotarget. 2017; 8(5):8069-8082.

PMID: 28039443 PMC: 5352383. DOI: 10.18632/oncotarget.14094.

References

Meckbach D, Bauer J, Pflugfelder A, Meier F, Busch C, Eigentler T . Survival according to BRAF-V600 tumor mutations--an analysis of 437 patients with primary melanoma. PLoS One. 2014; 9(1):e86194. PMC: 3901680. DOI: 10.1371/journal.pone.0086194. View

Davies H, Bignell G, Cox C, Stephens P, Edkins S, Clegg S . Mutations of the BRAF gene in human cancer. Nature. 2002; 417(6892):949-54. DOI: 10.1038/nature00766. View

Curtin J, Fridlyand J, Kageshita T, Patel H, Busam K, Kutzner H . Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005; 353(20):2135-47. DOI: 10.1056/NEJMoa050092. View

Houben R, Becker J, Kappel A, Terheyden P, Brocker E, Goetz R . Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis. J Carcinog. 2004; 3:6. PMC: 420489. DOI: 10.1186/1477-3163-3-6. View

Greaves W, Verma S, Patel K, Davies M, Barkoh B, Galbincea J . Frequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112 cases of melanoma. J Mol Diagn. 2013; 15(2):220-6. PMC: 5707183. DOI: 10.1016/j.jmoldx.2012.10.002. View

Shinozaki M, Fujimoto A, Morton D, Hoon D . Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas. Clin Cancer Res. 2004; 10(5):1753-7. DOI: 10.1158/1078-0432.ccr-1169-3. View

Broekaert S, Roy R, Okamoto I, van den Oord J, Bauer J, Garbe C . Genetic and morphologic features for melanoma classification. Pigment Cell Melanoma Res. 2010; 23(6):763-70. PMC: 3107973. DOI: 10.1111/j.1755-148X.2010.00778.x. View

Long G, Menzies A, Nagrial A, Haydu L, Hamilton A, Mann G . Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol. 2011; 29(10):1239-46. DOI: 10.1200/JCO.2010.32.4327. View

Qu K, Pan Q, Zhang X, Rodriguez L, Zhang K, Li H . Detection of BRAF V600 mutations in metastatic melanoma: comparison of the Cobas 4800 and Sanger sequencing assays. J Mol Diagn. 2013; 15(6):790-5. DOI: 10.1016/j.jmoldx.2013.07.003. View

10.

Bauer J, Buttner P, Murali R, Okamoto I, Kolaitis N, Landi M . BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site. Pigment Cell Melanoma Res. 2011; 24(2):345-51. PMC: 3107974. DOI: 10.1111/j.1755-148X.2011.00837.x. View

11.

Whiteman D, Pavan W, Bastian B . The melanomas: a synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of origin. Pigment Cell Melanoma Res. 2011; 24(5):879-97. PMC: 3395885. DOI: 10.1111/j.1755-148X.2011.00880.x. View

12.

Baiter M, Schuler G, Hartmann A, Schneider-Stock R, Heinzerling L . Pathogenetic Implications of BRAF Mutation Distribution in Stage IV Melanoma Patients. Dermatology. 2015; 231(2):127-33. DOI: 10.1159/000381849. View

13.

Heinzerling L, Baiter M, Kuhnapfel S, Schuler G, Keikavoussi P, Agaimy A . Mutation landscape in melanoma patients clinical implications of heterogeneity of BRAF mutations. Br J Cancer. 2013; 109(11):2833-41. PMC: 3844905. DOI: 10.1038/bjc.2013.622. View